Huadong Medicine (SHE:000963) Hangzhou Zhongmei Huadong Pharmaceutical received clinical trial approval from China's National Medical Products Administration for its HDM4002 experimental drug, according to a Thursday filing with the Shenzhen bourse.
The trial targets patients with primary IgA nephropathy, a chronic kidney disease, who are at risk of disease progression. The drug helps reduce kidney function loss.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments